Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated (PRLD) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PRLD · as of Jun 9, 2026
Activity summary
Buy transactions
6
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Prelude Therapeutics Incorporated insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
PRLD insider buying and selling by quarter
PRLD insider selling · PRLD insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · PRLD ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PRLD executive sell shares · PRLD board member insider trading · PRLD insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Other | 1,407,000 | $141 | Form 4 |
| Apr 21, 2026 | Bonita David P Director | Purchase | 1,689,189 | $7.50M⚡ | Form 4 |
| Apr 21, 2026 | Bonita David P Director | Purchase | 1,126,126 | $5.00M⚡ | Form 4 |
| Apr 21, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,689,189 | $7.50M⚡ | Form 4 |
| Apr 21, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,126,126 | $5.00M⚡ | Form 4 |
| Oct 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Oct 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $5K | Form 4 |
| Jul 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Jul 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $3K | Form 4 |
| Apr 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Apr 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $2K | Form 4 |
| Mar 25, 2025 | Combs Andrew Chief Chemistry Officer | Purchase | 100,000 | $69K | Form 4 |
| Mar 25, 2025 | Vaddi Krishna CEO · Director | Purchase | 675,000 | $467K | Form 4 |
| Mar 21, 2025 | Vaddi Krishna CEO · Director | Purchase | 15,000 | $11K | Form 4 |
| Mar 20, 2025 | Vaddi Krishna CEO · Director | Purchase | 5,416 | $4K | Form 4 |
| Mar 17, 2025 | Vaddi Krishna CEO · Director | Purchase | 9,106 | $7K | Form 4 |
| Mar 14, 2025 | Vaddi Krishna CEO · Director | Purchase | 29,999 | $23K | Form 4 |
| Mar 13, 2025 | Vaddi Krishna CEO · Director | Purchase | 50,000 | $36K | Form 4 |
| Mar 12, 2025 | Vaddi Krishna CEO · Director | Purchase | 47,500 | $34K | Form 4 |
| Jan 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Jan 4, 2025 | Huang Jane President, CMO | Other | 3,859 | $5K | Form 4 |
| Dec 31, 2024 | Vaddi Krishna CEO · Director | Purchase | 5,000 | $6K | Form 4 |
| Dec 30, 2024 | Vaddi Krishna CEO · Director | Purchase | 10,000 | $12K | Form 4 |
| Dec 23, 2024 | Combs Andrew Chief Chemistry Officer | Purchase | 60,000 | $82K | Form 4 |
| Dec 20, 2024 | Combs Andrew Chief Chemistry Officer | Purchase | 3,075 | $4K | Form 4 |
RA CAPITAL MANAGEMENT, L.P.
10 percent owner
Date
Apr 27
Shares
1,407,000
Price
$0.00
Value
$141
Bonita David P
Director
Date
Apr 21
Shares
1,689,189
Price
$4.44
Value
$7.50M ⚡
Bonita David P
Director
Date
Apr 21
Shares
1,126,126
Price
$4.44
Value
$5.00M ⚡
ORBIMED ADVISORS LLC
Director
Date
Apr 21
Shares
1,689,189
Price
$4.44
Value
$7.50M ⚡
ORBIMED ADVISORS LLC
Director
Date
Apr 21
Shares
1,126,126
Price
$4.44
Value
$5.00M ⚡
Combs Andrew
Chief Chemistry Officer
Date
Mar 25
Shares
100,000
Price
$0.69
Value
$69K
Vaddi Krishna
CEO · Director
Date
Mar 25
Shares
675,000
Price
$0.69
Value
$467K
Combs Andrew
Chief Chemistry Officer
Date
Dec 23
Shares
60,000
Price
$1.37
Value
$82K
Combs Andrew
Chief Chemistry Officer
Date
Dec 20
Shares
3,075
Price
$1.15
Value
$4K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PRLD insider trading
PRLD insider trades
Prelude Therapeutics Incorporated (PRLD) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Huang Jane (President, CMO), Bonita David P (Director), ORBIMED ADVISORS LLC (Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. PRLD insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Prelude Therapeutics Incorporated's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PRLD insider trading · 5 questionsThe insiders of Prelude Therapeutics Incorporated (PRLD) include executives and directors such as Huang Jane (President, CMO), Bonita David P (Director), ORBIMED ADVISORS LLC (Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026